{"id":"NCT01895452","sponsor":"Alkermes, Inc.","briefTitle":"An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","officialTitle":"A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2016-06","completion":"2016-06","firstPosted":"2013-07-10","resultsPosted":"2017-08-25","lastUpdate":"2017-08-25"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 9072, Low Dose","otherNames":[]},{"type":"DRUG","name":"ALKS 9072, High Dose","otherNames":[]}],"arms":[{"label":"ALKS 9072, Low Dose","type":"EXPERIMENTAL"},{"label":"ALKS 9072, High Dose","type":"EXPERIMENTAL"}],"summary":"This is an extension of a previous study (ALK9072-003EXT). The purpose of this study is to continue to evaluate the long-term safety and durability of effect of ALKS 9072 in subjects with stable schizophrenia, and to allow subjects who are doing well on ALKS 9072 to continue treatment.","primaryOutcome":{"measure":"Number and Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to 12 months","effectByArm":[{"arm":"ALKS 9072, Low","deltaMin":21,"sd":null},{"arm":"ALKS 9072, High","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":57,"countries":["United States","Bulgaria","Malaysia","Philippines","Romania","Russia","South Korea","Ukraine"]},"refs":{"pmids":["33761928","32841554"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Insomnia","Nasopharyngitis","Diarrhoea","Toothache"]}}